Results of the first human clinical studies confirm that a new yogurt fights the bacteria that cause gastritis and stomach ulcers with what researchers describe as almost vaccine-like effects, Japanese scientists reported at the 2009 National Meeting of the American Chemical Society, held in Salt Lake City.
According to lead investigator Hajime Hatta, of Kyoto Women's University, the suppression of stomach ulcer-causing Helicobacter pylori infection could be achieved by drinking yogurt fortified with urease antibody harvested from chicken eggs. The bacterium uses urease to attach to and infect the stomach lining.
The probiotic yogurt, which is sold as Dr Piro in Japan and as Gut in Korea,was tested in 42 people with H. pylori. The volunteers consumed two cups daily of either plain yogurt or yogurt containing the antibody for four weeks. Levels of urea, a byproduct of urease, decreased significantly in the antibody group when compared with the control group, indicating reduced bacterial activity, the researchers noted. The antibody was eventually destroyed by stomach acid, but not before having its beneficial effect. Although the yogurt appears less effective than antibiotics for reducing levels of H. pylori, it is a lot easier to take and can be eaten daily as part of regular dietary routine, Dr Hatta added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze